222 mg vs 444 mg
Compare the two amounts most often mentioned in community fenbendazole protocols and see how each fits into a weekly schedule.
Read the 222 mg vs 444 mg guideExplore fenbendazole 222 mg and 444 mg schedules, the Joe Tippens protocol, the Makis combination protocol, and standalone research calculators for fenbendazole, ivermectin and BPC-157.
Short answer: there is no FDA-approved fenbendazole dosage for humans. The figures below describe publicly discussed community schedules, not a medical recommendation.
A combination oncology protocol that pairs ivermectin with a benzimidazole (fenbendazole) plus metabolic support. Choose a severity tier — both doses are set automatically, and you can fine-tune each with its own slider.
Loading your personalized calendar…
🛒 Get the products for this protocol
There is no FDA-approved fenbendazole dosage for humans. This tool does not prescribe a dose. It organizes commonly searched, publicly discussed schedules so you can compare amounts, dosing days, rest days and safety considerations before speaking with a licensed clinician.
Compare the two amounts most often mentioned in community fenbendazole protocols and see how each fits into a weekly schedule.
Read the 222 mg vs 444 mg guideVisualize dosing and rest days, set a start date, and download the same day-by-day educational schedule shown on the page.
Open the fenbendazole calculatorReview the lack of an approved human dose, limited clinical evidence, liver-injury reports and the need to discuss interactions with a clinician.
Read the fenbendazole dosage guideExplore the widely discussed 222 mg, 3-days-on / 4-days-off schedule alongside the protocol's commonly cited adjuncts.
Review a community-described fenbendazole and ivermectin combination schedule with adjustable weight and protocol tiers.
Compare flat-dose research schedules, 222 mg and 444 mg amounts, safety zones, weekly dosing patterns and a dated calendar.
Use these evidence-focused guides to understand what the protocols claim, what is actually known, and where the evidence remains limited.